Moventig (Naloxegol)

Naloxegol, the active ingredient in Moventig, is a peripherally acting µ‑opioid receptor antagonist presented as an oral tablet. It is indicated for the treatment of opioid‑induced constipation in adults who are receiving opioid therapy for chronic pain, helping to restore normal bowel function without compromising analgesia.

GNH USA supplies Moventig as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide under strict quality standards. The company adheres to EU GMP guidelines and offers reliable logistics for timely delivery across multiple regions.

Naloxegol is used to manage opioid‑induced constipation, a gastrointestinal side effect of opioid therapy.

- Opioid‑induced constipation in chronic non‑cancer pain: increases bowel movement frequency and improves stool consistency. - Opioid‑induced constipation in cancer pain: reduces constipation severity and enhances patient comfort. - Opioid‑induced constipation in postoperative pain management: facilitates gastrointestinal recovery and normalizes bowel habits.

Naloxegol may cause adverse reactions that vary in frequency and severity.

Common Side Effects: - Abdominal pain: mild to moderate discomfort in the stomach area. - Diarrhea: increased frequency of loose stools. - Nausea: feeling of queasiness or urge to vomit. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Intestinal obstruction: signs of severe abdominal pain and bloating. - Severe allergic reaction: rash, swelling, or difficulty breathing. - Elevated liver enzymes: abnormal blood test indicating possible liver stress.

Before initiating therapy with Naloxegol, consider the following precautions.

- Assess renal function: dose adjustment may be required in severe renal impairment. - Avoid strong CYP3A4 inhibitors: concomitant use can increase drug exposure. - Monitor for signs of bowel obstruction: discontinue if obstruction is suspected. - Use with caution in patients with existing gastrointestinal disorders: evaluate risk versus benefit. - Store at ambient temperature: keep in the original pack, protect from moisture and light.

Naloxegol can interact with other medicines; awareness of interaction severity is essential.

Major Interactions (Avoid): - Ketoconazole (strong CYP3A4 inhibitor): avoid co‑administration. - Ritonavir (strong CYP3A4 inhibitor): avoid co‑administration.

Moderate Interactions (Monitor Closely): - Rifampin (CYP3A4 inducer): may reduce Naloxegol efficacy. - Diltiazem (moderate CYP3A4 inhibitor): may increase Naloxegol levels. - Anticholinergic agents: may exacerbate constipation symptoms.